EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis

Inhalierte Antibiotika zur Behandlung von Pneumonie bei invasiv beatmeten Intensivpatient:innen: Metaanalyse randomisierter klinischer Studien mit Trial Sequential Analysis

Nicolò Sella, Tommaso Pettenuzzo, Alessandro De Cassai, Francesco Zarantonello, Sabrina Congedi, Andrea Bruni, Eugenio Garofalo, Honoria Ocagli, Dario Gregori, Federico Longhini, Paolo Navalesi, Annalisa Boscolo und 1 weitere

Critical Care · 25.11.2024 · 28 (1)

DOI: 10.1186/s13054-024-05159-9 ↗

Auf einen Blick

11 RCTs mit 1472 Patient:innen zeigen: Adjuvante inhalierte Antibiotika erhöhten die mikrobiologische Eradikation, aber nicht klinische Erholung oder Überleben.

Fragestellung

Verbessern adjuvante inhalierte Antibiotika bei kritisch kranken Erwachsenen mit Pneumonie und invasiver Beatmung die mikrobiologische Eradikation?

Methode

Systematische Suche nach RCTs in Medline, Embase und Scopus bis 20. September 2024; Vergleich inhalierte antimikrobielle Therapie vs. i.v. Therapie oder i.v. plus Placebo; GRADE und TSA.

Ergebnisse

11 RCTs mit 1472 Patient:innen. Mikrobiologische Eradikation: OR 2,63 (95 %-KI 1,36–5,09; niedrige Evidenz). Bronchospasmus: OR 3,15 (95 %-KI 1,33–7,47; hohe Evidenz).

Einschränkungen

Niedrige Evidenz für den Primärendpunkt; hohes Risiko für Publikationsbias.

Schlussfolgerung der Autor:innen

Im Vergleich zur alleinigen i.v. Therapie war adjuvantes inhalatives Antibiotikum mit häufigerer mikrobiologischer Eradikation verbunden, nicht aber mit besserer klinischer Erholung oder Überleben.

Kernaussagen

  • Mikrobiologische Eradikation häufiger unter inhalativen Antibiotika
  • Bronchospasmus trat häufiger auf
  • Kein Unterschied bei klinischer Erholung oder Überleben

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Critical Care, online erschienen am 25.11.2024. Verfasst von Nicolò Sella und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Anesthesia and Intensive Care, Padua University Hospital, Padua, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Intensive Care Units, Randomized Controlled Trials as Topic, Respiration, Artificial. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of inhaled antibiotics for treating pneumonia in invasively ventilated patients offers a direct approach, allowing for high local concentrations of the drug in the lower respiratory tract while simultaneously reducing systemic toxicity. However, the real efficacy and safety of nebulized antibiotics remain unclear. The aim of the present is to assess among critically adult patients with pneumonia and invasive ventilation, whether receiving adjuvant inhaled antibiotics improves the rate of microbiological eradication.

Methods

A comprehensive literature search of randomized clinical trials (RCTs) was conducted (from inception until September 20, 2024, PROSPERO-CRD592906) across Medline, Embase, and Scopus. Randomized controlled trials, enrolling intensive care units (ICU) patients with pneumonia and comparing nebulized antimicrobial therapy (inhaled group) with intravenous antimicrobial treatment or intravenous antimicrobial therapy plus inhaled placebo (control group), were included. The primary outcome was the rate of microbiological eradication after treatment. Secondary outcomes were the rate of clinical recovery, the incidence of drug-related adverse events, ICU and hospital mortality. A qualitative analysis was conducted according to the GRADE framework. Data were pooled using an odds-ratio analysis. The heterogeneity and reliability of our results were evaluated using the I 2 -statistic and trial sequential analysis (TSA), respectively.

Results

A total of 11 RCTs (1472 patients) met the inclusion criteria. Compared to controls, the use of adjuvant inhaled antibiotics determined a greater rate of microbiological eradication (OR 2.63, 95% CI 1.36–5.09; low certainty of evidence). The TSA confirmed the reliability of our primary outcome. Moreover, nebulized antibiotics increased the risk of bronchospasm (OR 3.15, 95% CI 1.33–7.47; high evidence), while nephrotoxicity, clinical recovery, ICU and hospital survival (either in the case of pneumonia caused by MDR bacteria or not) were not different between groups.

Conclusions

In conclusion, compared to the sole intravenous therapy, the use of adjuvant inhaled antibiotics for treatment of pneumonia in invasively ventilated critically ill patients was associated with a greater incidence of microbiological eradication (low GRADE and high risk of publication bias), but not with clinical recovery and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsIntensive Care UnitsRandomized Controlled Trials as TopicRespiration, ArtificialHumansAdministration, InhalationPneumonia

Stichwörter der Autor:innen

AntibioticsInfectionInhaledMulti-drug resistantMulti-drug resistant organismNebulizedTreatment

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Institute of Anesthesia and Intensive Care, Padua University Hospital, Padua, Italy.
  • Department of Medicine (DIMED), Section of Anaesthesiology and Intensive Care, University of Padua, 13, Vincenzo Gallucci Street, 35125, Padua, PD, Italy.
  • Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
  • Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
  • Institute of Anesthesia and Intensive Care, Padua University Hospital, Padua, Italy. paolo.navalesi@unipd.it.
  • Department of Medicine (DIMED), Section of Anaesthesiology and Intensive Care, University of Padua, 13, Vincenzo Gallucci Street, 35125, Padua, PD, Italy. paolo.navalesi@unipd.it.

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Sella, N., Pettenuzzo, T., De Cassai, A., Zarantonello, F., Congedi, S., Bruni, A., Garofalo, E., Ocagli, H., Gregori, D., Longhini, F., Navalesi, P., Boscolo, A., & PADOVA ICU Group (2024). Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis. Critical Care, 28(1). https://doi.org/10.1186/s13054-024-05159-9

Vancouver

Sella N, Pettenuzzo T, De Cassai A, Zarantonello F, Congedi S, Bruni A, et al. Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis. Critical Care. 2024;28(1). doi:10.1186/s13054-024-05159-9

BibTeX
@article{Sella2024,
  author = {Sella, Nicolò and Pettenuzzo, Tommaso and De Cassai, Alessandro and Zarantonello, Francesco and Congedi, Sabrina and Bruni, Andrea and Garofalo, Eugenio and Ocagli, Honoria and Gregori, Dario and Longhini, Federico and Navalesi, Paolo and Boscolo, Annalisa and PADOVA ICU Group, PADOVA ICU Group},
  title = {Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis},
  journal = {Critical Care},
  year = {2024},
  volume = {28},
  number = {1},
  doi = {10.1186/s13054-024-05159-9}
}
Kostenlos starten →